
Overview
Background
Associate Professor Jakob Begun is the IBD Group leader in the Immunity, Infection, and Inflammation Program at Mater Research University of Queensalnd, and has a basic and translational laboratory at the Translational Research Institute in Brisbane. He is an Associate Professor in the University of Queensland Faculty of Medicine. After completing his Bachelor of Science at Cornell University Jakob attended Cambridge University where he completed an MPhil in Biochemistry. He then moved on to Harvard Medical School where he completed his MD and PhD in genetics studying the host pathogen interaction using C. elegans as a model system. He completed his clinical training in internal medicine at Brigham and Women’s hospital and went on to complete general gastroenterology training at Massachusetts General Hospital (MGH) as well as advanced training in the treatment of Inflammatory Bowel Disease (IBD).
Dr Begun first joined Mater Research - University of Queensland in 2014, and at the same time received a clinical staff appointment in Gastroenterology at the Mater Hospital Brisbane. His clinical activities are focussed on the treatment and mangement of patients with IBD. He is the director of the IBD unit at the Mater Hospital Brisbane and at the Mater Young Adult Health Centre Brisbane .In January 2015 he was awarded the University of Queensland Reginald Ferguson Fellowship in Gastroenterology to support his research activity. He leads a basic and translational laboratory at the Translational Research Institute investigating the interaction between the innate immune system and the gut microbiome, as well as genetic contributions to disease. He also performs clinical research examining predictors of response to therapy, minimising barriers of care for adolescents and young adults with IBD, improving outcomes in pregnancy and IBD, and the use of intestinal ultrasound in IBD. He is the chair of the Gastroenterology Society of Australia-IBD Faculty and of the president of the Gastroenterology Network of Intestinal Ultrasound (GENIUS).
Availability
- Associate Professor Jakob Begun is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Biology, Cornell University
- Doctoral Diploma of Medicine, Harvard University
- Doctor of Philosophy of Genetics, Harvard University
- Member, Gastroenterological Society of Australia, Gastroenterological Society of Australia
- Fellow, Royal Australasian College of Physicians, Royal Australasian College of Physicians
Research impacts
Inflammatory bowel disease(IBD) is a complex disease with genetic and environmental triggers. The microbiota is one of the biggest environmental contributors and interest in its impact on human health and disease is a growing. Studies in IBD have led the way in identifying disease associated microbial signals, but has not yet led to any new therapies.
As a clinician-scientist I am driven by my patients’ needs to address all aspects of their disease: including genetic and environmental risk factors, disease monitoring, and developing novel therapeutics. My tranlsational research program contributes to KNOWLEDGE IMPACT by discovering the function of IBD-susceptibility genes and anti-inflammatory bio-actives produced by the gut microbiota. My clinical research program advances HEALTH IMPACT by optimizing patient monitoring through evidence-based use of biochemical tests and imaging technology.
-Knowledge Impact. My research into the interaction between IBD susceptibility genes and bacterial handling has been highly cited, and led to an NHMRC collaborative project grant.
-Health Impact. My research program into advances in patient monitoring has led to the application for faecal calprotectin testing to be covered by the Medicare Benefit Scheme – which will have a direct impact on patient monitoring in the clinic. Additionally my monitoring research into the use of intestinal ultrasound has led to the formation of the Gastroenterology Network of Intestinal Ultrasound and the increase in ultrasound use in IBD patients in Australia.
Works
Search Professor Jakob Begun’s works on UQ eSpace
2022
Journal Article
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Cheon, Jae Hee, Paridaens, Kristine, Awadhi, Sameer Al, Begun, Jakob, Fullarton, John R, Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Dignass, Axel U and Travis, Simon PL (2022). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi: 10.5217/ir.2022.00006
2022
Journal Article
Secreted NF-κB suppressive microbial metabolites modulate gut inflammation
Giri, Rabina, Hoedt, Emily C., Khushi, Shamsunnahar, Salim, Angela A., Bergot, Anne-Sophie, Schreiber, Veronika, Thomas, Ranjeny, McGuckin, Michael A., Florin, Timothy H., Morrison, Mark, Capon, Robert J., Ó Cuív, Páraic and Begun, Jakob (2022). Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 39 (2) 110646, 110646. doi: 10.1016/j.celrep.2022.110646
2022
Journal Article
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
Louis, Edouard, Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Dignass, Axel U, Magro, Fernando, Márquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Freddi, Matthew J and Travis, Simon Pl (2022). Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 9 (1) e000853, e000853. doi: 10.1136/bmjgast-2021-000853
2022
Journal Article
Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages
Tran, Thao Thanh, Mathmann, Carmen D., Gatica-Andrades, Marcela, Rollo, Rachel F., Oelker, Melanie, Ljungberg, Johanna K., Nguyen, Tam T. K., Zamoshnikova, Alina, Kummari, Lalith K., Wyer, Orry J. K., Irvine, Katharine M., Melo-Bolívar, Javier, Gross, Annette, Brown, Darren, Mak, Jeffrey Y. W., Fairlie, David P., Hansford, Karl A., Cooper, Matthew A., Giri, Rabina, Schreiber, Veronika, Joseph, Shannon R., Simpson, Fiona, Barnett, Timothy C., Johansson, Jörgen, Dankers, Wendy, Harris, James, Wells, Timothy J., Kapetanovic, Ronan, Sweet, Matthew J. ... Blumenthal, Antje (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 18 (1) e1010166, e1010166. doi: 10.1371/journal.ppat.1010166
2022
Journal Article
Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis
Movva, Ramya, Murtaza, Nida, Giri, Rabina, Png, Chin Wen, Davies, Julie, Alabbas, Saleh, Oancea, Iulia, O'Cuiv, Páraic, Morrison, Mark, Begun, Jakob and Florin, Timothy H. (2022). Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. Gastro Hep Advances, 1 (3), 359-374. doi: 10.1016/j.gastha.2021.12.008
2021
Journal Article
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Dignass, Axel U., Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Fullarton, John R., Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R., Narula, Neeraj, Rydzewska, Grazyna and Travis, Simon P. L. (2021). Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 57 (4), 1-8. doi: 10.1080/00365521.2021.2015801
2021
Journal Article
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero
Flanagan, Emma, Prentice, Ralley, Wright, Emily K., Gibson, Peter R., Ross, Alyson L., Begun, Jakob, Sparrow, Miles P., Goldberg, Rimma, Rosella, Ourania, Burns, Megan, Kiburg, Katerina V. and Bell, Sally J. (2021). Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Alimentary Pharmacology and Therapeutics, 55 (6), 700-704. doi: 10.1111/apt.16739
2021
Journal Article
The psychosocial burden of inflammatory bowel disease in adolescents and young adults
Halloran, Jessica, McDermott, Brett, Ewais, Tatjana, Begun, Jakob, Karatela, Shamshad, D'Emden, Helen, Corias, Christian and Denny, Simon (2021). The psychosocial burden of inflammatory bowel disease in adolescents and young adults. Internal Medicine Journal, 51 (12) imj.15034, 2027-2033. doi: 10.1111/imj.15034
2021
Journal Article
Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22
Elshaer, Dana, Moniruzzaman, Md., Ong, Yi Theng, Qu, Zhi, Schreiber, Veronika, Begun, Jakob and Popat, Amirali (2021). Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. Biomaterials Science, 9 (22), 7402-7411. doi: 10.1039/d1bm01352a
2021
Journal Article
Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement
Ilvemark, Johan F. K. F., Hansen, Tawnya, Goodsall, Thomas M., Seidelin, Jakob B., Al-Farhan, Heba, Allocca, Mariangela, Begun, Jakob, Bryant, Robert V., Carter, Dan, Christensen, Britt, Dubinsky, Marla C., Gecse, Krisztina B., Kucharzik, Torsten, Lu, Cathy, Maaser, Christian, Maconi, Giovanni, Nylund, Kim, Palmela, Carolina, Wilson, Stephanie R., Novak, Kerri and Wilkens, Rune (2021). Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement. Journal of Crohn's and Colitis, 16 (4), 554-580. doi: 10.1093/ecco-jcc/jjab173
2021
Journal Article
Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial
Ewais, T., Begun, J., Kenny, M., Hay, K., Houldin, Evan, Chuang, Kai-Hisang, Tefay, M. and Kisely, S. (2021). Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. Journal of Psychosomatic Research, 149 110594, 110594. doi: 10.1016/j.jpsychores.2021.110594
2021
Journal Article
Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity
Weerakoon, Harshi, Straube, Jasmin, Lineburg, Katie, Cooper, Leanne, Lane, Steven, Smith, Corey, Alabbas, Saleh, Begun, Jakob, Miles, John J., Hill, Michelle M. and Lepletier, Ailin (2021). Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. Clinical and Translational Immunology, 10 (9) e1334, e1334. doi: 10.1002/cti2.1334
2021
Journal Article
Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas
De Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053
2021
Journal Article
SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease
Prentice, Ralley E., Rentsch, Clarissa, Al‐Ani, Aysha H., Zhang, Eva, Johnson, Douglas, Halliday, John, Bryant, Robert, Begun, Jacob, Ward, Mark G., Lewindon, Peter J., Connor, Susan J., Ghaly, Simon and Christensen, Britt (2021). SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease. GastroHep, 3 (4), 212-228. doi: 10.1002/ygh2.473
2021
Journal Article
Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol
Gu, Bonita, De Gregorio, Michael, Pipicella, Joseph Louis, Vande Casteele, Niels, Andrews, Jane M., Begun, Jakob, Connell, William, D'Souza, Basil, Gholamrezaei, Ali, Hart, Ailsa, Liew, Danny, Radford-Smith, Graham, Rimola, Jordi, Sutherland, Tom, Toong, Catherine, Woods, Rodney, Wu, Yang, Xuan, Wei, Williams, Astrid-Jane, Ng, Watson, Ding, Nik Sheng and Connor, Susan (2021). Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ open, 11 (7) 043921, e043921. doi: 10.1136/bmjopen-2020-043921
2021
Conference Publication
Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study
De Gregorio, M., Lee, T., Krishnaprasad, K., Amos, G., An, Y. K., Bastian-Jordan, M., Begun, J., Borok, N., Brown, D. J. M., Cheung, W., Connor, S., Gerstenmaier, J., Gilbert, L. E., Gilmore, R., Gu, B., Kutaiba, N., Lee, A., Mahy, G., Srinivasan, A., Thin, L., Thompson, A., Welman, C. J., Yong, E. X., De Cruz, P., van Langenberg, D., Sparrow, M. and Ding, N. S. (2021). Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study. 16th Congress of ECCO, Online, 2-3 & 8-10 July 2021. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjab076.523
2021
Journal Article
IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease
Henden, Andrea S., Koyama, Motoko, Robb, Renee J., Forero, Adriana, Kuns, Rachel D., Chang, Karshing, Ensbey, Kathleen S., Varelias, Antiopi, Kazakoff, Stephen H., Waddell, Nicole, Clouston, Andrew D., Giri, Rabina, Begun, Jakob, Blazar, Bruce R., Degli-Esposti, Mariapia A., Kotenko, Sergei V., Lane, Steven W., Bowerman, Kate L., Savan, Ram, Hugenholtz, Philip, Gartlan, Kate H. and Hill, Geoffrey R. (2021). IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 138 (8), 722-737. doi: 10.1182/blood.2020006375
2021
Journal Article
pH – responsive colloidal carriers assembled from β-lactoglobulin and epsilon poly-l-lysine for oral drug delivery
Pujara, Naisarg, Giri, Rabina, Yau Wong, Kuan, Qu, Zhi, Rewatkar, Prarthana, Moniruzzaman, Md., Begun, Jakob, Ross, Benjamin P., McGuckin, Michael and Popat, Amirali (2021). pH – responsive colloidal carriers assembled from β-lactoglobulin and epsilon poly-l-lysine for oral drug delivery. Journal of Colloid and Interface Science, 589, 45-55. doi: 10.1016/j.jcis.2020.12.054
2021
Conference Publication
So many therapies—So little data: How to choose? Session two summary
Begun, Jakob (2021). So many therapies—So little data: How to choose? Session two summary. Takeda IBD Symposium IBD 2020: Right Therapy, Right Patient, Right Time#Choosing Wisely, Online, 5 September 2020. Richmond, VIC Australia: Wiley-Blackwell. doi: 10.1111/jgh.15450
2021
Journal Article
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease
Goodsall, Thomas M., Jairath, Vipul, Feagan, Brian G., Parker, Claire E., Nguyen, Tran M., Guizzetti, Leonardo, Asthana, Anil K., Begun, Jakob, Christensen, Britt, Friedman, Antony B., Kucharzik, Torsten, Lee, Andrew, Lewindon, Peter J., Maaser, Christian, Novak, Kerri L., Rimola, Jordi, Taylor, Kirstin M., Taylor, Stuart A., White, Lauren S., Wilkens, Rune, Wilson, Stephanie R., Wright, Emily K., Bryant, Robert V. and Ma, Christopher (2021). Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease. Alimentary Pharmacology and Therapeutics, 53 (8), 873-886. doi: 10.1111/apt.16288
Funding
Current funding
Supervision
Availability
- Associate Professor Jakob Begun is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Novel and real-world use of Janus Kinase inhibitors for the management of Inflammatory Bowel Disease
Principal Advisor
-
Doctor Philosophy
Microbial Regulation of Host Inflammatory Pathways in Inflammatory Bowel Disease
Principal Advisor
Other advisors: Professor Mark Morrison
-
Doctor Philosophy
Study of TOfacitinib for the treatment of chronic Pouchitis
Principal Advisor
Other advisors: Professor Gerald Holtmann
-
Doctor Philosophy
Study of TOfacitinib for the treatment of chronic Pouchitis
Principal Advisor
Other advisors: Professor Gerald Holtmann
-
Doctor Philosophy
Reducing post-operative Crohn's disease recurrence
Principal Advisor
Other advisors: Professor David Clark, Dr Rabina Giri
-
Doctor Philosophy
Defining the Role of the Mucosa-Associated Microbiota in Digestive Health and Disease Using Novel ex-vivo Combinations of Microbe Culture with Metagenomics
Associate Advisor
Other advisors: Professor Mark Morrison
-
Doctor Philosophy
Investigating immunomodulatory function of gut microbiome and FXR pathway in IBD
Associate Advisor
Other advisors: Dr Rabina Giri
-
Doctor Philosophy
Bacteria x Archaea Interactions in Crohn's disease
Associate Advisor
Other advisors: Professor Mark Morrison
-
Doctor Philosophy
Medicinal chemistry of new Nature-inspired treatments for Inflammatory Bowel Disease (IBD)
Associate Advisor
Other advisors: Dr Angela Salim, Dr Zeinab Khalil, Professor Rob Capon
-
Doctor Philosophy
Designer Nanoparticles for Oral and Targeted Delivery of Protein Therapeutics
Associate Advisor
Other advisors: Dr Md Moniruzzaman, Professor Amirali Popat
-
Doctor Philosophy
Designer Nanoparticles for Oral and Targeted Delivery of Protein Therapeutics
Associate Advisor
Other advisors: Dr Md Moniruzzaman, Professor Amirali Popat, Dr Rabina Giri
Completed supervision
-
2024
Doctor Philosophy
Australia Ustekinumab Real-world Observational Research (AURORA)
Principal Advisor
-
2024
Doctor Philosophy
Drugs from Bugs: Harnessing the host-microbe interactions that modulate the immune responses in Inflammatory Bowel Disease
Principal Advisor
Other advisors: Dr Angela Salim, Professor Mark Morrison
-
2017
Master Philosophy
Delivery of Interleukin-22 using Mesoporous Silica Nanoparticles for the Treatment of Murine Colitis
Principal Advisor
Other advisors: Professor Amirali Popat
-
2024
Doctor Philosophy
Defining the Role of the Mucosa-Associated Microbiota in Digestive Health and Disease Using Novel ex-vivo Combinations of Microbe Culture with Metagenomics
Associate Advisor
Other advisors: Professor Mark Morrison
-
2023
Doctor Philosophy
Structure-function relationships of the mucosa-associated microbiota in Crohn's disease
Associate Advisor
Other advisors: Professor Gerald Holtmann, Professor Mark Morrison
-
2023
Doctor Philosophy
Mindfulness Based Cognitive Therapy for Youth with Inflammatory Bowel Disease and Depression: Understanding Mindfulness in the Context of Depression and Inflammation
Associate Advisor
Other advisors: Professor Steve Kisely
-
2022
Master Philosophy
Targeting Intestinal Epithelial Cell-Derived Interleukin-23 (p19) To Improve Intestinal Barrier Integrity in Inflammatory Bowel Disease
Associate Advisor
Other advisors: Dr Ran Wang
-
2021
Doctor Philosophy
Exploring the gut-liver axis and immunity in paracetamol-induced toxicity
Associate Advisor
Other advisors: Dr Ran Wang
-
2019
Doctor Philosophy
Investigation of Wnt pathway inhibition on host cell control of Listeria monocytogenes infection
Associate Advisor
Other advisors: Professor Antje Blumenthal
Media
Enquiries
Contact Associate Professor Jakob Begun directly for media enquiries about:
- adolescent
- autophagy
- Crohn's disease
- Inflammatory Bowel Disease
- ulcerative colitis
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: